|By Marketwired .||
|July 21, 2014 10:11 AM EDT||
OTTAWA, ONTARIO -- (Marketwired) -- 07/21/14 -- Editors Note: There is a photo associated with this press release.
The National Research Council of Canada (NRC) and KalGene Pharmaceuticals are proud to announce an agreement to co-develop a new treatment against aggressive brain cancers.
By combining their research, NRC and KalGene are targeting glioblastomas, which are severe brain tumours associated with a median patient survival of about 15 months. The collaboration couples KalGene's proprietary therapeutic antibody with NRC's single domain antibodies to enable delivery inside the brain, a promising strategy that may lead to improved outcomes for patients. Acting as carriers, NRC's antibodies will shuttle KalGene's antibody across the challenging blood-brain barrier to target the tumour cells in the brain.
-- The blood-brain barrier is composed of tightly woven cells that safeguard the brain by repelling harmful agents such as bacteria, while allowing the passage of critical nutrients. Overcoming the barrier is a significant challenge in addressing many diseases affecting the brain; virtually 100% of large molecule medicines are unable to cross the barrier. -- NRC has engineered a pipeline of single domain antibodies that exploit the mechanisms needed for the entry of nutrients in order to enable the delivery of medicine, like a Trojan horse. -- KalGene is committed to oncology programs that improve clinical and survival outcomes through precision medicine, which seeks to predict which patients will respond to a particular therapy in advance of treatment.
"NRC is proud to add significant value to and accelerate development of KalGene's promising treatment, which may lead to improved outcomes for patients."
Dr. Roman Szumski, Vice-President of Life Sciences at the National Research Council of Canada
"We are very much looking forward to our collaboration with NRC. This partnership will certainly help accelerate the global development and commercialization of our oncology innovation, and allow KalGene to bring innovative personalized oncology products to patients."
Dr. T. Nathan Yoganathan, President and Chief Executive Officer, KalGene Pharmaceuticals
To view the photo associated with this press release, please visit the following link: http://media3.marketwire.com/docs/NRC_and_KalGene_agreement.jpg.
Jul. 30, 2016 11:30 PM EDT Reads: 1,323
Jul. 30, 2016 10:30 PM EDT Reads: 1,940
Jul. 30, 2016 09:45 PM EDT Reads: 1,494
Jul. 30, 2016 09:45 PM EDT Reads: 1,318
Jul. 30, 2016 09:30 PM EDT Reads: 1,528
Jul. 30, 2016 07:30 PM EDT Reads: 1,763
Jul. 30, 2016 07:30 PM EDT Reads: 1,318
Jul. 30, 2016 07:00 PM EDT Reads: 2,776
Jul. 30, 2016 05:00 PM EDT Reads: 1,309
Jul. 30, 2016 04:30 PM EDT Reads: 584
Jul. 30, 2016 04:30 PM EDT Reads: 1,125
Jul. 30, 2016 04:30 PM EDT Reads: 2,283
Jul. 30, 2016 04:15 PM EDT Reads: 653
Jul. 30, 2016 02:30 PM EDT Reads: 1,075
Jul. 30, 2016 02:00 PM EDT Reads: 542